In-home HPV Screening vs Usual Care: Number of Participants That Completed Uptake of Cervical Cancer Screening
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.263 | 0.254 | 0.272 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.174 | 0.166 | 0.181 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | 0.0891 | 0.0776 | 0.1 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 1.51 | 1.43 | 1.6 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 1.7 | 1.58 | 1.82 | log | ClinicalTrials.gov | |
| Number needed to treat, for one more participant with the outcome on In-home HPV Screening than on Usual Care | 11.2 | 9.95 | 12.9 | from the risk difference interval | ClinicalTrials.gov |
Groups 2
Group 2 names the comparator: usual care.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | In-home HPV Screening | Usual care PLUS a mailed in-home high-risk HPV testing kit (accompanied by an invitational letter, research information sheet, and illustrated instructions for using the kit). Usual care consists of patient-, provider-, clinic- and systems-level services to promote adherence to Pap screening, including an annual birthday letter with Pap screening reminders, telephone outreach from primary care providers, and automatic alerts in the electronic medical record for overdue women.~Mailed in-home high-risk HPV testing kit~Usual care | 2,618 | 9,960 | OG000 | ClinicalTrials.gov |
| Group 2 | Usual Care | Usual care. Usual care consists of patient-, provider-, clinic- and systems-level services to promote adherence to Pap screening, including an annual birthday letter with Pap screening reminders, telephone outreach from primary care providers, and automatic alerts in the electronic medical record for overdue women.~Usual care | 1,719 | 9,891 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | SECONDARY | ClinicalTrials.gov |
| Title | Number of Participants That Completed Uptake of Cervical Cancer Screening | ClinicalTrials.gov |
| Description | Uptake of cervical cancer screening is defined as either: \[1\] receipt of a Pap or co-test; \[2\] self-sample hrHPV-positive (16/18-negative) OR unsatisfactory AND receipt of follow-up diagnostic testing (Pap or co-test or colposcopy); \[3\] self-sample HPV16/18-positive; or \[4\] self-sample hrHPV-negative)~Using an intent-to-treat approach, we will use log-binomial regression to estimate the relative risk for cervical cancer screening uptake for the in-home HPV screening arm versus the usual care arm.~We will also use log-binomial regression to estimate the effects of EMR-derived patient characteristics (e.g. age, race/ethnicity, geocoded socioeconomic status, geocoded distance form primary care clinic, insurance type, time since last Pap test, tobacco use, obesity, and Charlson comorbidity score) on cervical cancer screening uptake, stratified subdivided by randomization arm. | ClinicalTrials.gov |
| Time frame | Assessed for up to 6 months post-randomization | ClinicalTrials.gov |
| Population | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Randomized Trial of In-Home Cervical Cancer Screening in Underscreened Women | ClinicalTrials.gov |
| NCT number | NCT02005510 | ClinicalTrials.gov |
| Phases | NA | ClinicalTrials.gov |
| Conditions | Cervical Cancer | ClinicalTrials.gov |
| Interventions | Mailed in-home high-risk HPV testing kit, Usual care | ClinicalTrials.gov |
| Lead sponsor | University of Washington | ClinicalTrials.gov |
| Results first posted | 2020-09-16 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT02005510?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.